Literature DB >> 21111956

Staging and prognosis of cutaneous melanoma.

Paxton V Dickson1, Jeffrey E Gershenwald.   

Abstract

Staging of cutaneous melanoma continues to evolve through identification and rigorous analysis of potential prognostic factors. In 1998, the American Joint Committee on Cancer (AJCC) Melanoma Staging Committee developed the AJCC melanoma staging database, an international integrated compilation of prospectively accumulated melanoma outcome data from several centers and clinical trial cooperative groups. Analysis of this database resulted in major revisions to the TNM staging system reflected in the sixth edition of the AJCC Cancer Staging Manual published in 2002. More recently, the committee's analysis of an updated melanoma staging database, including prospective data on more than 50,000 patients, led to staging revisions adopted in the seventh edition of the AJCC Cancer Staging Manual published in 2009. This article highlights these revisions, reviews relevant prognostic factors and their impact on staging, and discusses emerging tools that will likely affect future staging systems and clinical practice.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21111956      PMCID: PMC3221385          DOI: 10.1016/j.soc.2010.09.007

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  73 in total

1.  Major response to imatinib mesylate in KIT-mutated melanoma.

Authors:  F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

2.  Conditional survival in gastric cancer: a SEER database analysis.

Authors:  Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas
Journal:  Gastric Cancer       Date:  2007-09-26       Impact factor: 7.370

3.  Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease.

Authors:  Tawnya L Bowles; Yan Xing; Chung-Yuan Hu; Kristi S Mungovan; Robert L Askew; George J Chang; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2010-04-06       Impact factor: 5.344

4.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

5.  Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.

Authors:  J Manola; M Atkins; J Ibrahim; J Kirkwood
Journal:  J Clin Oncol       Date:  2000-11-15       Impact factor: 44.544

Review 6.  The changing prognosis of melanoma.

Authors:  A C Buzaid; C M Anderson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

Review 7.  Prognostic factors in thin cutaneous malignant melanoma.

Authors:  S M Salman; G S Rogers
Journal:  J Dermatol Surg Oncol       Date:  1990-05

8.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001.

Authors:  Mehee Choi; Clifton D Fuller; Charles R Thomas; Samuel J Wang
Journal:  Gynecol Oncol       Date:  2008-03-07       Impact factor: 5.482

10.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more
  52 in total

1.  Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain.

Authors:  José Antonio Avilés-Izquierdo; Pablo Lázaro-Ochaita
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

2.  Surgical management of malignant melanoma of the lung.

Authors:  Ikenna Okereke
Journal:  Melanoma Manag       Date:  2015-11-24

Review 3.  New options for the adjuvant treatment of cutaneous melanoma?

Authors:  Amy M Weise; Lawrence E Flaherty
Journal:  Curr Oncol Rep       Date:  2014-11       Impact factor: 5.075

Review 4.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 5.  Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Authors:  Nicolas A Giraldo; J David Peske; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2019-01-10       Impact factor: 4.064

6.  Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.

Authors:  Hongliang Liu; Qingyi Wei; Jeffrey E Gershenwald; Victor G Prieto; Jeffrey E Lee; Madeleine Duvic; Elizabeth A Grimm; Li-E Wang
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

Review 7.  A new era in the treatment of melanoma: from biology to clinical practice.

Authors:  I Márquez-Rodas; S Martín Algarra; J A Avilés Izquierdo; S Custodio Cabello; M Martín
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

8.  Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.

Authors:  Axel Hauschild; James Larkin; Antoni Ribas; Brigitte Dréno; Keith T Flaherty; Paolo A Ascierto; Karl D Lewis; Edward McKenna; Qian Zhu; Yong Mun; Grant A McArthur
Journal:  JAMA Oncol       Date:  2018-10-01       Impact factor: 31.777

9.  Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

Authors:  James R Patrinely; Laura X Baker; Elizabeth J Davis; Haocan Song; Fei Ye; Douglas B Johnson
Journal:  Cancer       Date:  2020-05-28       Impact factor: 6.860

10.  GAB2 induces tumor angiogenesis in NRAS-driven melanoma.

Authors:  Y Yang; J Wu; A Demir; M Castillo-Martin; R D Melamed; G Zhang; M Fukunaga-Kanabis; R Perez-Lorenzo; B Zheng; D N Silvers; G Brunner; S Wang; R Rabadan; C Cordon-Cardo; J T Celebi
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.